Floatz logo

Niraparib

Molecular Mechanisms of Pharmacological Action

Xiaoxiang ChenSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Molecular Mechanisms of Pharmacological Action cohort.

Asset / SponsorPhaseRating
Guanfacine
Maimonides Medical Center
Phase 4BB
Empagliflozin
Yonsei University
Phase 4BB
Pioglitazone
Yonsei University
Phase 4BB
SACUBITRIL VALSARTAN
Silesian Centre for Heart Diseases
Phase 4BB
Sorafenib
Sichuan Cancer Hospital and Research Institute
Phase 2B

View all 15 →

Same molecule, other indications

Niraparib is also rated in:

breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
ovarian neoplasmDormant
BB
Indicative ·
66 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →